Found: 14
Select item for more details and to access through your institution.
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 197, n. 2, p. 319, doi. 10.1007/s10549-022-06797-9
- By:
- Publication type:
- Article
Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes.
- Published in:
- PLoS ONE, 2012, v. 7, n. 5, p. 1, doi. 10.1371/journal.pone.0036402
- By:
- Publication type:
- Article
Quantitative phosphoproteomic analysis of the PI3K-regulated signaling network.
- Published in:
- Proteomics, 2016, v. 16, n. 14, p. 1992, doi. 10.1002/pmic.201600118
- By:
- Publication type:
- Article
Phosphoproteome analysis of the MAPK pathway reveals previously undetected feedback mechanisms.
- Published in:
- Proteomics, 2016, v. 16, n. 14, p. 1998, doi. 10.1002/pmic.201600119
- By:
- Publication type:
- Article
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
- Published in:
- Nature, 2010, v. 464, n. 7287, p. 431, doi. 10.1038/nature08833
- By:
- Publication type:
- Article
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents.
- Published in:
- Journal of Cell Biology, 2008, v. 183, n. 1, p. 101, doi. 10.1083/jcb.200801099
- By:
- Publication type:
- Article
Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer.
- Published in:
- Science Translational Medicine, 2010, v. 2, n. 48, p. 1, doi. 10.1126/scitranslmed.3000630
- By:
- Publication type:
- Article
Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours.
- Published in:
- Genes, Chromosomes & Cancer, 1999, v. 25, n. 2, p. 91, doi. 10.1002/(SICI)1098-2264(199906)25:2<91::AID-GCC3>3.0.CO;2-5
- By:
- Publication type:
- Article
Erratum: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.
- Published in:
- Nature, 2013, v. 502, n. 7470, p. 258, doi. 10.1038/nature12659
- By:
- Publication type:
- Article
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.
- Published in:
- Nature, 2013, v. 501, n. 7466, p. 232, doi. 10.1038/nature12441
- By:
- Publication type:
- Article
P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 9, p. 606, doi. 10.1093/jnci/djt054
- By:
- Publication type:
- Article
Low Proportion of BRCA1 and BRCA2 Mutations in Finnish Breast Cancer Families: Evidence for Additional Susceptibility Genes.
- Published in:
- Human Molecular Genetics, 1997, v. 6, n. 13, p. 2309, doi. 10.1093/hmg/6.13.2309
- By:
- Publication type:
- Article
Two independent polymorphisms at the 17β-hydroxysteroid dehydrogenase (EDH17B) gene (17q21).
- Published in:
- Human Molecular Genetics, 1993, v. 2, n. 6, p. 821
- By:
- Publication type:
- Article
An ATP-Site On-Off Switch That Restricts Phosphatase Accessibility of Akt.
- Published in:
- Science Signaling, 2012, v. 5, n. 223, p. 1, doi. 10.1126/scisignal.2002618
- By:
- Publication type:
- Article